Design, synthesis and evaluation of scutellarein- O -alkylamines as multifunctional agents for the treatment of Alzheimer's disease

European Journal of Medicinal Chemistry

Volumn 94, Issue , 2015, Pages 348-366

  Sang, Zhipei ^a   Qiang, Xiaoming ^a   Li, Yan ^a   Yuan, Wen ^a   Liu, Qiang ^a   Shi, Yikun ^c   Ang, Wei ^a   Luo, Youfu ^b   Tan, Zhenghuai ^c   Deng, Yong ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c Sichuan Academy of Chinese Medicine Sciences   (China)

Author keywords

Ab aggregation inhibitors; Acetylcholinesterase inhibitors; Alzheimer's disease; Metal chelating agents; Multifunctional agents; Scutellarein O alkylamines

Indexed keywords

4' [3 (4 BENZYLPIPERAZIN 1 YL)PROPOXY] 5,6,7 TRIMETHOXYFLAVONE; 4' [3 (4 METHYLPIPERAZIN 1 YL)PROPOXY] 5,6,7 TRIMETHOXYFLAVONE; 4' [3 [(2 METHOXYBENZYL)(METHYL)AMINO]PROPOXY] 5,6,7 TRIMETHOXYFLAVONE; 4' [3 [(ETHYL)(2 METHOXYBENZYL)AMINO]PROPOXY] 5,6,7 TRIMETHOXYFLAVONE; 4' [3 [BENZYL(ETHYL)AMINO]PROPOXY] 5,6,7 TRIMETHOXYFLAVONE; 4' [3 [BENZYL(METHYL)AMINO]PROPOXY] 5,6,7 TRIMETHOXYFLAVONE; 4' [4 (4 BENZYLPIPERAZIN 1 YL)PROPOXY] 5,6,7 TRIMETHOXYFLAVONE; 4' [4 (4 METHYLPIPERAZIN 1 YL)PROPOXY] 5,6,7 TRIMETHOXYFLAVONE; 4' [4 [(2 METHOXYBENZYL)(METHYL)AMINO]PROPOXY] 5,6,7 TRIMETHOXYFLAVONE; 4' [4 [(ETHYL)(2 METHOXYBENZYL)AMINO]PROPOXY] 5,6,7 TRIMETHOXYFLAVONE; 4' [4 [BENZYL(ETHYL)AMINO]PROPOXY] 5,6,7 TRIMETHOXYFLAVONE; 4' [4 [BENZYL(METHYL)AMINO]PROPOXY] 5,6,7 TRIMETHOXYFLAVONE; 4' [6 [BENZYL(ETHYL)AMINO]PROPOXY] 5,6,7 TRIMETHOXYFLAVONE; 4' [6 [BENZYL(METHYL)AMINO]PROPOXY] 5,6,7 TRIMETHOXYFLAVONE; 5 HYDROXY 4' [3 [(ETHYL)(2 METHOXYBENZYL)AMINO]BUTOXY] 6,7 DIMETHOXYFLAVONE; ACETYLCHOLINESTERASE; ALIPHATIC AMINE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ANTIOXIDANT; CHELATING AGENT; CHOLINESTERASE INHIBITOR; CURCUMIN; DONEPEZIL; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; RIVASTIGMINE; SCUTELLAREIN; SCUTELLAREIN O ALKYLAMINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; AMINE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); APIGENIN; HYDROGEN PEROXIDE; PEPTIDE FRAGMENT; SCOPOLAMINE BROMIDE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICHOLINERGIC EFFECT; ANTIOXIDANT ACTIVITY; ARTICLE; CHELATION; CONTROLLED STUDY; DRUG DESIGN; DRUG MEGADOSE; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC50; LATENT PERIOD; MOLECULAR DOCKING; MOLECULAR MODEL; MOUSE; NEUROPROTECTION; NONHUMAN; OPTIMAL DRUG DOSE; PC12 CELL LINE; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; RAT; SCOPOLAMINE-INDUCED AMNESIA; STEP-DOWN PASSIVE AVOIDANCE TEST; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMICALLY INDUCED; CHEMISTRY; DOSE RESPONSE; MEMORY DISORDERS; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; AMINES; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIOXIDANTS; APIGENIN; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMANS; HYDROGEN PEROXIDE; MEMORY DISORDERS; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PC12 CELLS; PEPTIDE FRAGMENTS; RATS; SCOPOLAMINE HYDROBROMIDE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84924567657     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.02.063     Document Type: Article

References (43)

1. Alzheimer's Disease International, Policy brief: the global impact of dementia 2013-2050, http://www.alz.co.uk/research/G8-policy-brief.
2. N. Herrmann, S.A. Chau, I. Kircanski, K.L. Lanctot, Current and emerging drug treatment options for Alzheimer's disease: a systematic review, Drugs 71 (2011) 2031-2065.
3. Y. Huang, L. Mucke, Alzheimer mechanisms and therapeutic strategies, Cell 148 (2012) 1204-1222.
4. T. Sobow, Combination treatments in Alzheimer's disease: risks and benefits, Expert Rev. Neurother. 10 (2010) 693-702.
5. A. Cavalli, M.L. Bolognesi, A. Minarini, M. Rosini, V. Tumiatti, M. Recanatini, C. Melchiorre, Multi-target-directed ligands to combat neurodegenerative diseases, J. Med. Chem. 51 (2008) 347-372.
6. R. Morphy, Z. Rankovic, Designing multiple ligands-medicinal chemistry strategies and challenges, Curr. Pharm. Des. 15 (2009) 587-600.
7. A. Cavalli, M.L. Bolognesi, S. Capsoni, V. Andrisano, M. Bartolini, E. Margotti, A. Cattaneo, M. Recanatini, C. Melchiorre, A small molecule targeting the multifactorial nature of Alzheimer's disease, Angew. Chem. Int. Ed. Engl. 46 (2007) 3689-3692.
8. P.C. Trippier, K. Jansen Labby, D.D. Hawker, J.J. Mataka, R.B. Silverman, Target-and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers, J. Med. Chem. 56 (2013) 3121-3147.
9. R. Leon, A.G. Garcia, J. Marco-Contelles, Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease, Med. Res. Rev. 33 (2013) 139-189.
10. E. Scarpini, P. Scheltens, H. Feldman, Treatment of Alzheimer's disease: current status and new perspectives, Lancet Neurol. 2 (2003) 539-547.
11. M. Citron, Alzheimer's disease: strategies for disease modification, Nat. Rev. Drug Discov. 9 (2010) 387-398.
12. L.L. Guo, Z.Z. Guan, Y. Huang, Y.L. Wang, J.S. Shi, The neurotoxicity of beta-amyloid peptide toward rat brain is associated with enhanced oxidative stress, inflammation and apoptosis, all of which can be attenuated by scu-tellarin, Exp. Toxicol. Pathol. 65 (2013) 579-584.
13. J.T. Zhu, R.C. Choi, J. Li, H.Q. Xie, C.W. Bi, A.W. Cheung, T.T. Dong, Z.Y. Jiang, J.J. Chen, K.W. Tsim, Estrogenic and neuroprotective properties of scutellarin from Erigeron breviscapus: a drug against postmenopausal symptoms and Alzheimer's disease, Planta Med. 75 (2009) 1489-1493.
14. H. Hong, G.Q. Liu, Protection against hydrogen peroxide-induced cytotoxicity in PC12 cells by scutellarin, Life Sci. 74 (2004) 2959-2973.
15. L. Qian, M. Shen, H. Tang, Y. Tang, L. Zhang, Y. Fu, Q. Shi, N.G. Li, Synthesis and protective effect of scutellarein on focal cerebral ischemia/reperfusion in rats, Molecules 17 (2012) 10667-10674.
16. X. Chen, L. Cui, X. Duan, B. Ma, D. Zhong, Pharmacokinetics and metabolism of the flavonoid scutellarin in humans after a single oral administration, Drug Metab. Dispos. 34 (2006) 1345-1352.
17. C. Gao, X. Chen, D. Zhong, Absorption and disposition of scutellarin in rats: a pharmacokinetic explanation for the high exposure of its isomeric metabolite, Drug Metab. Dispos. 39 (2011) 2034-2044.
18. X. Qiang, Z. Sang, W. Yuan, Y. Li, Q. Liu, P. Bai, Y. Shi, W. Ang, Z. Tan, Y. Deng, Design, synthesis and evaluation of genistein-O-alkylbenzylamines as potential multifunctional agents for the treatment of Alzheimer's disease, Eur. J. Med. Chem. 76 (2014) 314-331.
19. G.S. Mason, R. Hans, N.H. Max, 4′, 5, 6, 7-Oxygenated flavones and flavanones, J. Pharm. Sci. 2 (1964) 192-195.
20. C. Fruit, A. Turck, N. Ple, L. Mojovic, G. Queguiner, A new route to septorin via controlled metalations of pyrazines. Diazines XXX, Tetrahedron 57 (2001) 9429-9435.
21. H. Tokunaru, K. Hiroki, T. Masao, M. Miisuo, N. Mtisuru, Studies of the selective O-alkylation and dealkylation of flavonoids. VII. Partial dealkylation of 5, 6, 7-trioxygenated flavones and synthesis of pectolinarigenin and its analogues, Yakugaku Zasshi 105 (1985) 2232-2239.
22. M. Rosini, E. Simoni, A. Milelli, A. Minarini, C. Melchiorre, Oxidative stress in Alzheimer's disease: are we connecting the dots? J. Med. Chem. 57 (2014) 2821-2831.
23. D. Pratico, S. Sung, Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease, J. Alzheimer's Dis. 6 (2004) 171-175.
24. A. Davalos, C. Gomez-Cordoves, B. Bartolome, Extending applicability of the oxygen radical absorbance capacity (ORAC-fluorescein) assay, J. Agric. Food Chem. 52 (2004) 48-54.
25. G.L. Ellman, K.D. Courtney, V. Andres Jr., R.M. Feather-Stone, A new and rapid colorimetric determination of acetylcholinesterase activity, Biochem. Pharmacol. 7 (1961) 88-95.
26. M. Rosini, E. Simoni, M. Bartolini, A. Cavalli, L. Ceccarini, N. Pascu, D.W. McClymont, A. Tarozzi, M.L. Bolognesi, A. Minarini, V. Tumiatti, V. Andrisano, I.R. Mellor, C. Melchiorre, Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush, J. Med. Chem. 51 (2008) 4381-4384.
27. Y. He, P.F. Yao, S.B. Chen, Z.H. Huang, S.L. Huang, J.H. Tan, D. Li, L.Q. Gu, Z.S. Huang, Synthesis and evaluation of 7, 8-dehydrorutaecarpine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease, Eur. J. Med. Chem. 63 (2013) 299-312.
28. L. Pezzementi, K. Johnson, I. Tsigelny, J. Cotney, E. Manning, A. Barker, S. Merritt, Amino acids defining the acyl pocket of an invertebrate cholines-terase, comparative biochemistry and physiology. Part B, Biochem. Mol. Biol. 136 (2003) 813-832.
29. W. Xing, Y. Fu, Z. Shi, D. Lu, H. Zhang, Y. Hu, Discovery of novel 2, 6-disubstituted pyridazinone derivatives as acetylcholinesterase inhibitors, Eur. J. Med. Chem. 63 (2013) 95-103.
30. R. Squitti, C. Salustri, Agents complexing copper as a therapeutic strategy for the treatment of Alzheimer's disease, Curr. Alzheimer Res. 6 (2009) 476-487.
31. X. Huang, M.P. Cuajungco, C.S. Atwood, M.A. Hartshorn, J.D. Tyndall, G.R. Hanson, K.C. Stokes, M. Leopold, G. Multhaup, L.E. Goldstein, R.C. Scarpa, A.J. Saunders, J. Lim, R.D. Moir, C. Glabe, E.F. Bowden, C.L. Masters, D.P. Fairlie, R.E. Tanzi, A.I. Bush, Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction, J. Biol. Chem. 274 (1999) 37111-37116.
32. P. Camps, X. Formosa, C. Galdeano, D. Munoz-Torrero, L. Ramirez, E. Gomez, N. Isambert, R. Lavilla, A. Badia, M.V. Clos, M. Bartolini, F. Mancini, V. Andrisano, M.P. Arce, M.I. Rodriguez-Franco, O. Huertas, T. Dafni, F.J. Luque, Pyrano[3, 2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetyl-cholinesterase-and beta-amyloid-directed anti-Alzheimer compounds, J. Med. Chem. 52 (2009) 5365-5379.
33. M.L. Bolognesi, V. Andrisano, M. Bartolini, R. Banzi, C. Melchiorre, Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinesterase-induced amyloid-beta aggregation, J. Med. Chem. 48 (2005) 24-27.
34. A. Alvarez, C. Opazo, R. Alarcon, J. Garrido, N.C. Inestrosa, Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils, J. Mol. Biol. 272 (1997) 348-361.
35. S.S. Hindo, A.M. Mancino, J.J. Braymer, Y. Liu, S. Vivekanandan, A. Ramamoorthy, M.H. Lim, Small molecule modulators of copper-induced Abeta aggregation, J. Am. Chem. Soc. 131 (2009) 16663-16665.
36. M.I. Fernandez-Bachiller, C. Perez, N.E. Campillo, J.A. Paez, G.C. Gonzalez-Munoz, P. Usan, E. Garcia-Palomero, M.G. Lopez, M. Villarroya, A.G. Garcia, A. Martinez, M.I. Rodriguez-Franco, Tacrine-melatonin hybrids as multifunctional agents for Alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties, ChemMedChem 4 (2009) 828-841.
37. W. Yuan, Z.P. Sang, X.M. Qiang, Z.H. Tan, Y. Deng, Synthesis of pterostilbene and resveratrol carbamate derivatives as potential dual cholinesterase inhibitors and neuroprotective agents, Res. Chem. Intermed. 40 (2014) 787-800.
38. M.A. Abd-El-Fattah, N.F. Abdelakader, H.F. Zaki, Pyrrolidine dithiocarbamate protects against scopolamine-induced cognitive impairment in rats, Eur. J. Pharmacol. 723 (2014) 330-338.
39. S.H. Kwon, H.K. Lee, J.A. Kim, S.I. Hong, H.C. Kim, T.H. Jo, Y.I. Park, C.K. Lee, Y.B. Kim, S.Y. Lee, C.G. Jang, Neuroprotective effects of chlorogenic acid on scopolamine-induced amnesia via anti-acetylcholinesterase and anti-oxidative activities in mice, Eur. J. Pharmacol. 649 (2010) 210-217.
40. E.J. Kim, I.H. Jung, T.K. Van Le, J.J. Jeong, N.J. Kim, D.H. Kim, Ginsenosides Rg5 and Rh3 protect scopolamine-induced memory deficits in mice, J. Ethnopharmacol. 146 (2013) 294-299.
41. H. Zheng, M.B. Youdim, M. Fridkin, Selective acetylcholinesterase inhibitor activated by acetylcholinesterase releases an active chelator with neuro-rescuing and anti-amyloid activities, ACS Chem. Neurosci. 1 (2010) 737-746.
42. M. Bartolini, C. Bertucci, M.L. Bolognesi, A. Cavalli, C. Melchiorre, V. Andrisano, Insight into the kinetic of amyloid beta (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action, ChemBioChem 8 (2007) 2152-2161.
43. R. Gupta, L.K. Gupta, P.K. Mediratta, S.K. Bhattacharya, Effect of resveratrol on scopolamine-induced cognitive impairment in mice, Pharmacol. Reports 64 (2012) 438-444.